OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
靶点 |
|
描述 | D prostanoid receptor 2 (DP2) is selectively expressed by T helper 2 (Th2) lymphocytes, eosinophils, and basophils and mediates recruitment and activation of these cell types in response to prostaglandin D2 (PGD2)[1]. OC000459 is a potent, selective, and orally active DP2 antagonist. It potently displaces [3H] PGD2 from human recombinant DP2 (Ki = 13 nM), rat recombinant DP2 (Ki = 3 nM), and human native DP2 (Ki = 4 nM). OC000459 inhibited chemotaxis (IC50 = 0.028 μM) of human Th2 lymphocytes and cytokine production (IC50 = 0.019 μM) by human Th2 lymphocytes. OC000459 also inhibited the activation of Th2 cells and eosinophils in response to supernatants from IgE/anti-IgE-activated human mast cells[1]. OC000459 was found to be orally bioavailable in rats and effective in inhibiting blood eosinophilia induced by 13, 14-dihydro-15-keto-PGD2 (DK-PGD2) in this species (ED50 = 0.04 mg/kg p.o.) and airway eosinophilia in response to an aerosol of DK-PGD2 in guinea pigs (ED50 = 0.01 mg/kg p.o.)[1]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00290381 | Allergic Rhinitis | Phase 1 | Completed | - | United Kingdom ... 展开 >> National Heart & Lung Institute Clinical Studies Unit London, United Kingdom, SW3 6HP 收起 << |
NCT02660489 | Asthma Rhinov... 展开 >>irus Picornaviridae Infections Common Cold 收起 << | Phase 2 | Unknown | February 2018 | United Kingdom ... 展开 >> St Mary's Hospital Recruiting London, Greater London, United Kingdom, W2 1PG Contact: Hugo Farne, BMBCh MA 07590 250487 asthma.trial@imperial.ac.uk Contact: Maria-Belén Trujillo-Torralbo, BSc 07590 250487 asthma.trial@imperial.ac.uk 收起 << |
NCT00697281 | Allergic Rhinitis | Phase 2 | Completed | - | Austria ... 展开 >> Allergie Zentrum Wien West, Vienna Challenge Chamber Vienna, Austria, 1150 VIENNA 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.87mL 0.57mL 0.29mL |
14.35mL 2.87mL 1.44mL |
28.71mL 5.74mL 2.87mL |
CAS号 | 851723-84-7 |
分子式 | C21H17FN2O2 |
分子量 | 348.37 |
SMILES Code | CC1=C(CC2=NC3=C(C=CC=C3)C=C2)C2=C(C=CC(F)=C2)N1CC(O)=O |
MDL No. | MFCD18633254 |
别名 | OC000459 |
运输 | 蓝冰 |
InChI Key | FATGTHLOZSXOBC-UHFFFAOYSA-N |
Pubchem ID | 11462174 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, store in freezer, under -20°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|